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ABSTRACT 
 
Rasé, Viva Jeanne. Type 3 T helper cell and myeloid derived suppressor cell population 
dynamics in a mammary carcinoma model Unpublished Master of Science Thesis, 
University of Northern Colorado, 2020  
 
Immunotherapies that augment Type I immunity show robust responses in diffuse 
blood cancers yet remain relatively ineffective in breast and other solid tumor 
malignancies. Breast tumor resistance to immunotherapies is associated with polarization 
towards pro-tumor Type 2 immunity, as well as the expansion of a myeloid derived 
suppressor cell (MDSC) population that inhibits Type 1 T helper (Th) and CD8+ cytotoxic 
T cells. Does polarization toward Type 3 immunity play a role in mammary tumor 
formation? This question had not been investigated prior to these studies despite 
established relationships between MDSCs and Type 3 Th cells in other inflammatory 
pathologies. Therefore, we investigated involvement of Type 3 Th cells (Th17 and Th22) 
and their association with expanding MDSC populations in the 4T1 mouse mammary 
carcinoma model. When evaluated at multiple time points after 4T1 injection (days 7, 14, 
21, and 28), tumor infiltration of Th17 and Th22 cells was first detected at d 14, and Th17 
populations declined after this time while Th22 remained unchanged. In peripheral 
organs, Th17 increased by d 7 before declining, while Th22 were not elevated until later 
times. Only Th17 and MDSC expansion in the bone marrow were positively correlated, 
suggesting further that Th17 and Th22 are functionally distinct lineages and that MDSCs 
may play a role in Th17 fate determination in breast cancer. To further address a possible 
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relationship between MDSCs and Type 3 Th cells in mammary carcinoma, we used 
CRISPR-Cas9 to knock out tumor cell-specific production of interleukin (IL) -6 (IL6-
KO), which functions in Th maturation, myelopoiesis, and MDSC recruitment. Tumor-
resident Th17, Th22, and MDSCs did not change in IL-6 KO tumors, suggesting a limited 
role for IL-6 in local recruitment. However, induction of Th22 and MDSCs in peripheral 
tissues was significantly reduced with IL6-KO tumors, while Th17 cells were increased. 
These concomitant changes in peripheral Type 3 Th and MDSCs suggests direct 
functional interactions between these populations, yet additional studies are required to 
confirm this. To conclude, we identify and characterize a pro-tumor Type 3 Th immune 
response that accompanies MDSC expansion in a model of metastatic breast cancer. This 
is important because these populations are associated with reduced efficacy of cancer 
immunotherapies. 
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CHAPTER I 
INTRODUCTION 
Resistance to Cancer Immunotherapy 
 
In 2019 breast cancer was the leading cause of new cancer cases among American 
women and the second leading cause of cancer deaths in the US behind lung cancers (1). 
In the past decade, immunotherapies that involve training the patient’s immune system to 
recognize and kill cancer cells have been investigated as treatment for breast and other 
cancers. While targeted immunotherapies, especially immune checkpoint (PD-1 and 
CTLA-4) antibody therapy, have been shown to be effective in some forms of lymphoma 
(2), leukemia (3), and melanoma (4), similarly dramatic results have not been observed 
for solid tumor malignancies like breast cancer (5). Even with the advent of 
immunotherapies, breast cancer mortality rates have remained relatively constant (1), and 
recent clinical observations have suggested rare instances in which immunotherapy 
treatment may have resulted in harmful breast tumor hyper-progression (6). Thus, there is 
a definitive clinical need to understand why immunotherapies are failing in these solid 
tumors.  
Mechanisms of Resistance to Immunotherapy 
 
Currently, this resistance to immunotherapy is in part thought to arise because 
breast and other solid tumors present a much more logistically complex location to access 
because they cloak themselves in a milieu of immunosuppressive factors. Additionally, 
solid tumors are not a diffuse easily accessible liquid environment like blood. Due to the 
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variety and breadth of immune countermeasures elicited by solid cancers (7), a complete 
understanding of immunotherapy failure has yet to be realized, and additional 
mechanisms remain to be explored. One well-described barrier to successful 
immunotherapy is the recruitment of myeloid derived suppressor cells (MDSC), a 
population of immature myeloid cells that directly mitigate cytotoxic T and T helper (Th) 
cell potency – immune cell populations that checkpoint therapy hinges on for 
effectiveness. While breast cancers can recruit MDSCs, it is still unclear exactly how the 
tumor, host, and additional immune system components react to their expansion. It has 
been shown that breast tumors can cause polarization away from anti-tumor Type 1 
toward pro-tumor Type 2 immunity (8). Previous work done on MDSC in autoimmunity 
and parasitic infections suggests an interaction between MDSC and Type 3 immunity (9), 
defined here as the accumulation of Th17, Th22, and transitional Th1/17 cell populations. 
Surprisingly little has been done to investigate Type 3 immunity in the context of MDSC-
expanding mammary carcinoma. Thus, the studies described in this thesis aim to: 1) 
Describe the response of Type 3 Th immune cell populations- Th17, Th1/17 and Th22- in a 
murine model of mammary cancer; 2) Correlate the Type 3 Th responses with MDSC 
expansion; and 3) Determine the role of tumor derived interleukin (IL)-6 on MDSC and 
Th cell accumulation and polarization. This work is important because it identifies 
immune polarization and interaction mechanisms that lead to immunotherapy resistance. 
A proposed working model of potential cellular interactions is shown in Figure 1.  
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Specific Aims and Research Hypothesis 
 
A1  Characterize Type 3 Th recruitment by 4T1 mammary tumors.  
 
H1  Proportions of Type 3 Th immune cells (Th17, Th1/Th17, and Th22) will be 
elevated in the tumor and peripheral organs of 4T1 tumor-bearing mice 
compared to healthy controls.  
 
A2  Explore the relationship between MDSCs and the Type 3 immune 
response. 
 
H2  MDSC immune cell expansion will precede Type 3 expansion, suggesting 
MDSC involvement in systemic Type 3 recruitment. 
 
A3  Determine the role of tumor derived IL-6 on MDSC, Type 3 immune, and 
total Th recruitment 
  
H3  4T1 tumors deficient in IL-6 will recruit fewer MDSCs and Type 3 Th 
cells (Th17, Th1/Th17, and Th22) in tumors and peripheral tissues, while 
Type 1 Th cell recruitment will correspondingly increase.   
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Figure 1: Proposed interactions between 4T1 tumor cells, type 3 Th, and MDSCs; 
that are mediated by interleukin IL-6. In this predicted scenario, Type 3 Th cells will 
be recruited from naïve T cells by the 4T1 mammary carcinoma cells. We hypothesize 
that tumor-derived IL-6 is partly responsible for recruiting and skewing naïve T cells into 
Type 3 Th cells (Th17 Th1/17 and Th22), effectively expanding their population and 
creating the opportunity to have Type 3 cells recruited into the tumor. IL-6 also plays a 
role in fate determination of myeloid cells, leading to the expansion of MDSC from 
immature myeloid cells in the bone marrow (10). However, it is unknown if specifically 
removing tumor-derived IL-6 will mitigate MDSC expansion. Lastly, the relationship 
between Type 3 Th and MDSC expansion will be evaluated. 
 
  
? 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
Normal Immunity 
Adaptive and Innate Immunity   
Adaptive immunity. Th cells, cytotoxic T cells, and B cells are a part of the 
adaptive immune system and are characterized by eliciting antigen specific response 
through highly variable antigen receptors (11). Adaptive immunity can be broken down 
into two categories: humoral immunity and cellular immunity. Humoral immunity is 
often defined as B cell mediated formation and release of antigen specific 
immunoglobulins, also known as antibodies. Antibodies, among other functions, can 
opsonize pathogen for further recognition by innate phagocytotic immune cells. Cell 
mediated adaptive immunity generally does not involve antibody response and is often 
characterized by Th and cytotoxic T cell activation (11, 12).  
Innate immunity. Preceding adaptive immune response and thus Th cell control 
of immunity, the innate immune system must first recognize danger. These molecular 
danger signals are known as pathogen associated molecular patterns (PAMPs) or damage 
associated molecular patterns (DAMPS). PAMPs are highly conserved regions on 
pathogen such as lipopolysaccharide, peptidoglycan, and unmethylated CpG regions of 
DNA, (13) while DAMPs are intracellular contents released from damaged cells such as 
ATP, histones, and mitochondrial DNA (14). Innate immune dendritic cells (DC) and 
macrophage, also known as professional antigen presenting cells (APC), do not rely on a 
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specific antigen to be activated but instead act through recognition of danger signals by 
pattern recognition receptors (PRR), such as toll-like receptors (TLR), nod-like receptors 
(NLR), and RIG-I-like receptors (RLR) (12). These innate immune cells are further 
equipped to aid in Th activation and modulate the Type of immunity (15).  
T Cell Activation and T Cell  
Receptor Biology  
Unlike B cells that recognize antigen in its native form to activate (11), T cells 
with traditional a/b T cell receptor (TCR) require presentation of antigen peptide loaded 
on major histocompatibility complex (MHC), which is expressed on the surface of APC. 
There are two classes of MHC on which peptide antigen can be presented: MHC I and 
MHC II. The MHC class restricts T cell response to either cytotoxic T or Th recognition. 
Cytotoxic T cells recognize peptide loaded onto MHC I due to cluster of differentiation 
(CD) 8 co-receptor expression, while Th cells recognize peptide loaded MHC II due to 
CD4 co-receptor expression. MHC I and MCH II differ in cellular expression patterns, 
with MHCI expressed on the surface of all nucleated cells, allowing for cytotoxic T cell 
and natural killer (NK) cell monitoring of self-cells and subsequent deletion of self when 
an abnormal antigen is presented (15, 16). Due to the widespread expression of MHC I, 
cytotoxic T cell-mediated cell death is vital for surveillance and removal of virally 
infected cells and pre-malignant cells with mutated antigen, also termed cancer neo-
antigen (17, 18). Th1 cells play a further role in enhancing cytotoxic T cell accumulation 
and function through signaling of relevant cytokines such as interferon gamma (IFN-g)  
(19). MHC II is concerned mostly with extracellular-sourced antigens and is only 
expressed on professional APC (B cells, dendritic cells, and macrophages) with a 
functional phagolysosome.  B cell antigen presentation to T cells in the lymphoid follicles 
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(Tfh) is necessary for the development of a hyper-specific and effective antibody 
response, while presentation via the myeloid cells, especially DC, is a necessary bridge 
between innate and adaptive immunity required for the full resolution of a response to 
immunological threat (16).  
TCR interaction with peptide-loaded MHC accompanied by CD4 or CD8 co-
receptor stimulation is necessary but not sufficient to initiate T cell clonal expansion. Co-
stimulation must accompany TCR:MHC interaction for clonal expansion to ensue. This 
occurs through adequate upregulation of costimulatory molecules CD80 (B7.1) and 
CD86 (B7.2) on APCs, which stimulate CD28 on naïve T cells. Adequate co-stimulation, 
TCR engagement, and APC production of IL-2 are each necessary and altogether 
sufficient for T cell activation, and expansion. Without proper co-stimulation, T cells 
often undergo anergy (20). Anergy mechanisms involving immune checkpoints cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-
1) are covered later more extensively in the Immune Tolerance section.   
Types of Immunity Based  
on T Helper Cell  
Phenotype 
 
Broadly, there are three main types of immunity to threats/pathogens (with 
examples) the immune system is equipped to respond to: Type 1- intracellular (viruses), 
Type 2-large extracellular (helminth) and Type 3- small extracellular pathogens (bacteria 
and fungi). Each immunity type is ultimately mediated and maintained by the activation 
and polarization of specific adaptive CD4+ Th cells. Once activated, Th cells undergo 
clonal expansion (with respect to their specific TCR sequence) and produce a milieu of 
distinct cytokines that program and dictate further immune response specificity for a 
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given pathogen (21). Indeed, type of immunity was characterized by the response 
initiated following specific pathogen infection; however, the polarization of different 
types of immunity may occur in other contexts, an example being aberrant Type 3 
activation leading to autoimmunity (22). Characterizing the type of immune response 
instigated by cancer and other pathologies will be important in understanding the 
inappropriate immune responses that often accompany these disease states.  
T Helper Cell Polarization 
Amongst Type 1, 2, and 3 
 
 Th polarization follows naïve Th cell recognition of antigen and activation. 
Contingent on the specific danger signal, professional APCs produce a specific cytokine 
profile, which is necessary to polarize Th cells down an immunological lineage. Indeed, 
this encourages fate determination by promoting one type of immunity, which aligns with 
lineage restricted overexpression of specific transcription factors and cytokines. The 
clonal expansion of all Th broadly requires IL-2 stimulation, while distinct polarization of 
Th cells enabling the more pathogen specific responses requires specific stimulation as 
will be described below. As a general rule though, the cytokines that promote one 
category of polarized immunity will inhibit other Th subset formation, which leads to 
specialized Th cell mediated immunity following a specific immune challenge (23). The 
process of normal polarization will be described in the sections immediately following, 
while a potential role of polarization in cancer will be described in a later section. 
Type 1 Immunity 
Following a Type 1 challenge such as a viral infection, Th cells are stimulated and 
polarized to become Th1 cells by IL-12 and IFN-g secreting dendritic cells and 
macrophages (23) allowing for the upregulation of transcription factors T-bet, signal 
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transducer and activator of transcription (STAT) 4 and STAT1, which further polarize Th 
cells to the Th1 phenotype. Th1 cells then respond by producing more IFN-g facilitating 
(23) immunoglobin (IgG) 1, IgG2a and IgG3 B cell (clarify/rephrase) class switching (19, 
23); and recruitment of CD8+ cytotoxic T cells, M1 macrophages, and NK cells. These 
cellular responses further direct and specify Type 1 immunity (23). In addition to its viral 
target, Type 1 immunity is the major immune response required to clear pre-malignant, 
mutated ‘self’-cells (24). 
Type 2 Immunity 
Type 2 immunity is mediated by Th2 polarization dependent on local 
concentrations of IL-2 and IL-4 dendritic cells and macrophages (23), which leads to Th 
cell expression of transcription factors STAT6 and GATA-3, ultimately allowing for 
increased production of  IL-4, IL-5, and IL-13 (25). This response is accompanied by IgE 
B cell class switching and recruitment of mast cells, eosinophils, basophils, and M2 
macrophages (19, 25, 26). Type 2 immunity promotes a targeted response to large 
multicellular parasites, but in the context of cancer, it appears to foster tumor growth, 
likely because resources are misdirected away from Type 1 immunity (24). 
Type 3 Immunity 
T helper cell 22 versus T helper cell 17. Type 3 immunity is mediated by Th17 
and Th22 cells. In the late 1980s, Th cells were initially classified into two groups Th1 and 
Th2 (27). It was not until the mid-2000s that Th17 were identified as a distinct lineage 
subset (28, 29). In 2009 Th22 were identified as yet another unique Th subset (30); 
however, ever since the distinction between Th22 and Th17 cells has been hotly debated. 
This is in part due to limited studies highlighting functionally divergent roles of Th22 and 
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Th17 (31). To date, most studies of Th22 function have explored the immunomodulatory 
effects of IL-22 (32). Confoundingly, Th17 are also a source of IL-22, and therefore it 
remains unclear whether there is a distinct Th22 function. Additionally, many studies use 
in vitro Th22 polarization protocols that also stimulate Th17 differentiation, making 
interpretation of these results difficult. Recently, however, researchers have developed an 
in vitro differentiation protocol for Th22 that excludes Th17 differentiation. Studies 
evaluating Th17 versus Th22 functionality are sure to follow (31). 
Polarization towards type 3 T helper cells. Following a bacterial challenge, 
Th17 or Th22 fate determination is dictated chiefly by expression of transcription factor 
retinoic acid receptor related orphan nuclear receptor gamma t (RORgt). The Th17 
phenotype requires Th expression of RORgt promoting the ability to produce Type 3 
immune cytokines IL-17A and IL-17F. Polarization toward the Th22 lineage requires 
inhibition of RORgt expression, and as a consequence Th22 do not express IL-17A or IL-
17F (23). The polarization toward Th17 requires transforming growth factor beta-1 
(TGFb-1), IL-6, and IL-23; alternatively, Th22 requires the combination of IL-6, IL-23, 
and IL-1b (31). Th22 express IL-22, which is regulated in part by transcription factors 
aryl hydrocarbon receptor (AHR) and STAT3 (33). Interestingly, Th17 retain expression 
of IL-22. Th22 and Th17 mediated immunity to allow for the recruitment of neutrophils 
and MDSC. Type 3 immunity is elicited to target small extracellular pathogens; however, 
in the context of solid tumors, this response may be tumor protective (34). Again, this 
may arise because it draws finite resources from Type 1 immunity but could also directly 
stimulate IL-22 receptor (IL-22R) expressing epithelial cancers like breast cancer.  
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Interleukin 17 and interleukin 22 Synergy. Th cell co-expression of IL-22 and 
IL-17 may have additive or synergistic effects. In microbial infection, co-expression of 
IL-17 and IL-22 enhanced expression of anti-pathogen, pro-inflammatory markers 
CXCL8, IL-6, S100A8 and S100A9 (35, 36). Additionally, IL-22 and IL-17 are known to 
work in conjunction to protect against mucocutaneous infection (22). In airway 
inflammation, for example, IL-22 alone did not lead to a pro-inflammatory state, but the 
addition of both IL-22 and IL-17 incited airway inflammation. Specifically, this was 
mediated by Th17 and allowed for neutrophil recruitment to the airway (37). These 
additive properties of IL-17 and IL-22 may explain the perceived conflicting pro- and 
anti-inflammatory nature of IL-22.   
Resolution of Inflammation 
The polarization of Th to the proper category focuses the immune response to a 
given immunological challenge and is pertinent for timely resolution of inflammation. If 
an immune response is polarized toward the wrong type of immunity for a given 
pathogen, the immune system may not be properly equipped to fight it, thus prolonging 
inflammation and increased disease severity. A great example of this is 
following Mycobacterium leprae (M. leprae) infection, which causes leprosy. M. 
leprae is a small intracellular pathogen. Within cases of leprosy, there is a more severe 
illness known as lepromatous leprosy and less severe illness known as tuberculoid 
leprosy. In both instances leprosy is caused by M. leprae, however, the pathology of the 
disease is determined by whether the host elicits a type1 immune response as seen in 
tuberculoid leprosy or a misguided type 2 response as seen in lepromatous leprosy (38).  
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Following termination of an adaptive immune response, a select group of adaptive 
T cells and B cells, with a receptor repertoire specific to the antigen cleared, are 
maintained in the greater lymphocyte population. This adaptive memory allows for faster 
activation of the T cell and B cell response if a secondary challenge occurs (39). 
Following clearance of the pathogen, the immune responses must be dialed back 
and actively suppressed. In large, this occurs through recruitment of the CD4+ T 
regulatory (Treg) cells that can quell cytotoxic and Th expansion through the release of 
inhibitory cytokines (TGFb, IL-10, and IL-35) (40), cell lysis, metabolic disruption and 
targeting of dendritic cells to inhibit Th expansion (41, 42). MDSCs are also known to 
support Treg expansion, and consequently, both Treg and MDSCs are tumor protective 
(43). Treg and MDSC are necessary to maintain peripheral tolerance to self and prevent 
autoimmune reactions (41, 44).  
Immune Tolerance 
Immunological tolerance prevents inappropriate immune responses targeted to 
self-antigen and occurs by either central or peripheral tolerance selection mechanisms. 
Central tolerance occurs in the thymus after T cells undergo VDJ rearrangement of the 
TCR. VDJ rearrangement results in a broad repertoire of antigen specificity. Due to the 
extensive repertoire of TCR specificity, some T cells may be inherently auto reactive. 
When naïve T cells are challenged by thymic epithelium or myeloid cell with self-peptide 
loaded MHC. Tissue specific self-peptide expression is mediated by autoimmune 
regulator in thymocytes. If TCR high affinity binding occurs the T cell is either deleted 
by apoptosis, undergoes further receptor editing, or is induced to become a Treg. Since not 
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all self-antigens are presented in the thymus, some auto-reactive T cells will eventually 
escape central tolerance (45).  
Thus, peripheral tolerance mechanisms outside the thymus exist to prevent further 
T cell autoimmunity most often mediated by immunosuppressive Treg cells, lack of co-
stimulatory molecules, and immune checkpoints. The process and outcome of peripheral 
tolerance and may result in T cell apoptosis, anergy or Treg formation (45). A specific 
mechanism of T cell peripheral tolerance or inflammatory response resolution is referred 
to as “Immune Checkpoints.” This mechanism relies on inhibitory receptors expressed by 
T cells and APC that impede adequate T cell co-stimulation and TCR signaling. The most 
common checkpoint receptors are CTLA-4 and PD-1 both expressed on T cells. CTLA-4 
is upregulated on T cells after activation and binds to costimulatory molecules CD80 and 
CD86 on APCs, which reduces co-stimulation and eventually may leads to T cell anergy. 
Indeed anergy occurs because of the lack of proper co-stimulatory molecules for T cell to 
interact with upon MHC:TCR interaction as a control mechanism to avoid an unsolicited 
autoimmune response.  PD-1 is expressed on hyperactivated and thus exhausted T cells. 
It binds programmed death ligand-1 (PD-L1), which is constitutively expressed and 
active on a variety of myeloid and tumor cells. The interaction of these two proteins 
stimulates T cell apoptosis, which again eliminates potentially auto-reactive T cells in the 
periphery (20).  
Immune Surveillance 
As alluded to above, a primary function of the immune system is to surveil ‘self’ 
cells for abnormalities. Thus, the immune system is the primary defense mechanism 
against transformed tumor cells that may emerge following the failure of cellular-level, 
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innate, tumor suppressor mechanisms. Immune recognition of tumor neoantigen is 
hypothesized to be the primary route of direct cancer cell elimination. This response is 
initiated by Type I MHC damage signals followed by an IFN-g-driven Type 1 immune 
response mediated by Th1 cells (46). Macrophages then acquire a pro-inflammatory M1 
phenotype with the hallmark of increased antigen presenting capability and increased 
production of cytokines IL-6, IFN-g, and tumor necrosis factor alpha (TNF-a) (47). 
Cytotoxic T cells and NK cells are then recruited and can facilitate direct malignant cell 
death via perforin membrane pore formation, TNF-related apoptosis inducing ligand 
(TRAIL), FAS/FASL, and granzyme b (46).  Due to these responses, cancerous cells are 
often killed before they pose a major concern. However, clearly, some tumor cells are not 
deleted, which can be followed by further tumor immune escape.  
Tumor Immune Escape 
Immune surveillance is protective against pre-malignant cells, and thus for 
carcinoma cells to successfully form a growing tumor mass, they must overwhelm or 
evade the body’s immune response resulting in ‘tumor escape’ (48–53). Tumor escape is 
often driven by stochastic misappropriation of surface molecule expression. Specific 
examples include T cell anergy resulting from the upregulation of co-inhibitory 
checkpoint molecules CTLA-4 and PD-1 described above, or downregulation of MHC I 
leading to an inability for cytotoxic T cells to surveil for abnormal self-antigen. In 
addition to surface marker regulation, tumor cells also manipulate their local milieu of 
cytokines to preferentially attract tumor promoting immune cells such as M2 
macrophages, MDSC and Treg. Tumoral cytokines such as TGF-b1 and IL-6 enhance pro-
tumor immune cell phenotype while aiding in tumor growth, local but disorganized 
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angiogenesis, and eventual metastases (54). This recruitment is often initiated by 
polarization away from an anti-tumor type 1 response toward an ineffectual type 2 or type 
3 response (55). Again, many of the studies detailed in this thesis aim to better 
understand these tumor escape mechanisms in mammary carcinoma to improve 
immunotherapy treatments. 
Cancer Immunity 
Checkpoint Immunotherapy  
Cancer 
 
Checkpoint inhibitor antibodies have been developed to target CTLA-4 and PD-1/ 
PD-L1 described above. These antibodies have shown clinical success in hematological 
tumors and solid tumors with a high neoantigen burden, leading to tumor regression and 
considerable gains in patient survival (56–60). Unfortunately, not all patients have 
benefited equally from checkpoint inhibition as non- or poor responders, adverse immune 
events, and tumor hyper-progression have also been reported (6, 61–64). These reports of 
hyper-progression suggest, paradoxically, that releasing inhibitory control of the CTLA-4 
and PD-1/PD-L1 axes on the immune system can aid in tumor progression under certain 
immunological circumstances. These disparate outcomes clearly indicate that we need 
more information on a cancer patient’s immunological status to ensure that checkpoint 
and other immunotherapies are delivered into an optimally effective immune context. 
Case in point the only predictors of therapeutic tumor hyper-progression across all tumor 
types following checkpoint inhibitor treatment is female sex, which is concerning when 
treating breast cancer patients with checkpoint immunotherapy (61).  
The variable tumor responses to checkpoint immunotherapy are likely explained 
primarily by the phenotype and quantity of tumor infiltrating lymphocytes (TIL)- the 
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immune cells that directly occupy the tumor mass (65). However, several other systemic 
immune factors may also play a role in checkpoint therapy effectiveness. Upregulation of 
immune inhibitory cells such as MDSCs can impair CD8+ cytotoxic T cell activation, and 
more broadly, inhibit effector Th cell function (66). Another important factor is tumor 
immune polarization as a means of immune evasion by reducing an anti-tumor type 1 
response and amplifying a pro-tumor type 2 or type 3 response (67–70). Thus, it is 
important to understand the Type of T cell-mediated immunity a tumor elicits before 
administering checkpoint inhibitors that preserve or amplify T cell responses.  
Immune Polarization in Breast  
and Other Carcinomas 
 
Breast cancer-mediated polarization away from an effective type 1 response 
toward an ineffective, helminth-targeting type 2 response was previously characterized 
(71, 72), yet no investigations have addressed possible polarization toward type 3 
immune responses normally geared for microbial infection. T cell polarization toward a 
type 3 immune response involving Th17 or Th22 cells has been defined in mouse models 
and human cases of cervical, ovarian, prostate, and gastric cancers (34, 68, 73–77), 
indicating that there is precedent for its exploration in models of breast cancer. Further, 
increased expansion of type 3 Th cells has been observed in autoimmune diseases such as 
lupus erythematosus, autoimmune encephalomyelitis, and autoimmune arthritis, as well 
as in H. pylori infections. Intriguingly, type 3 responses in these inflammatory conditions 
are also associated with a significant MDSC response (9, 44, 78). As indicated 
previously, many breast malignancies lead to the recruitment of MDSCs (43). Is there is a 
link between this MDSC response and polarization toward type 3 Th cells that has largely 
been ignored? 
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Type 3 Immunity and Cancer:  
T Helper Cell 22 and 
 Interleukin 22  
 
T helper cell 22. Th22 cells were first described as a terminally differentiated Th 
subset in inflammatory skin diseases: psoriasis, atopic dermatitis, and contact dermatitis 
(30). To our knowledge, Th22 have not been explored in the context of breast cancer, 
though they have been characterized to some extent in a handful of other malignancies. 
Reinforcing the clinical relevance of this cell type, Th22 were significantly elevated in the 
blood and tumors of human patients in gastric, cervical and ovarian cancer (77, 79–81). 
Th22 accumulation in blood was correlated with poor prognosis and lymph node 
metastasis in patients with stage III and IV gastric and ovarian cancer (79–81). In a study 
investigating Th22 in human colon cancer, it was found that Th22 cells supported tumor 
formation, being positively correlated with cancer proliferation and loss of cell cycle 
control in adjacent target cells through polycomb repressive complex 2 (82). In the above 
examples and elsewhere, Th22 cells have been generally implicated a shaping an 
aggressive tumor microenvironment through secretion of IL-22 and potentially other 
undefined factors. 
Under normal physiological conditions, Th22 cells express CCR10 in both human 
and mouse (30, 83), which is a receptor for CCL27 and CCL28 expressed in skin and 
mucosal tissues (84, 85). Since these chemokine receptors and their ligands are essential 
for cell migration and where they congregate, Th22 cells tend to reside in epithelial 
barriers (skin and gut) (30). As such, in humans, Th22 typically comprise of about 1-2% 
of peripheral blood mononuclear cells and the majority are thought to reside in epithelial 
barrier tissues and aid in wound healing (86). CCR10 has been shown to be 
  
18 
overexpressed on breast cancer and melanoma tumor cells activated by elevated levels of 
CCL27 and CCL28, which aids in enhanced tumor invasion and migration (84, 87, 88). 
Given that normal epithelial tissues express the CCL27 and CCL28 ligands, if an 
alternative tumor source of these chemokine ligands are present, does this attract Th22 
cells to the tumor? It is clear now from our studies that Th22 are recruited in the 4T1 
mammary carcinoma model, and we believe (though have not yet tested) that tumor 
derived CCL27/CCL28 ligands may underlie this recruitment and local delivery of pro-
tumor IL-22. 
Interleukin 22 ligand. Cellular sources of IL-22 are limited mostly to immune 
cells: Th1, Th17, Th22, type 3 innate lymphoid cells 3 (ILC3) and NK cells (33). STAT3 
and AHR are important drivers in IL-22 transcription initiation and c-maf and suppressor 
of cytokine signaling 3 (SOCS3) downregulate IL-22 production (33). IL-22 is 
recognized by a heterodimeric receptor IL-22R1 and IL-10Rb, and although immune 
cells produce IL-22, they do not express IL-22R1 and therefore, are unresponsive to IL-
22 stimulus (89). 
IL-22 is a dual-function cytokine that appears to be both immune protective or 
pro-inflammatory depending on the context. IL-22 acts on epithelial target tissues to 
enhance survival and proliferation, increase expression of antimicrobial peptide, and aid 
in wound healing. The anti- or pro-inflammatory nature of IL-22 may be a consequence 
of target tissue specific response or acute versus chronic inflammation (33). In ulcerative 
colitis, a chronic inflammatory disease of the colon, hypomorph mutations in the gene 
loci encoding IL-22 and IL-10Rb are disease risk factors (90, 91), suggesting that IL-22 
is critical for maintaining an anti-inflammatory state in the colon. However, IL-22 can 
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promote inflammation in psoriatic lesions in the skin (92) and is upregulated in the serum 
of patients with granulomatous mastitis (93).  
In breast carcinoma, IL-22 has been investigated for its pro-tumor effects 
including: promotion of epithelial cell transformation (94, 95), increased invasiveness 
and migration (96), chemotherapy resistance (97), and uncoincidentally, stimulation of 
epithelial-mesenchymal transition (EMT) (98). However, the role of IL-22 in shaping the 
tumor immune environment remains undefined. In normal epithelial target tissues, IL-22 
signaling leads to increased activation of Janus kinase (JAK)/STAT pathways specifically 
activation of STAT1, STAT3 and STAT5 followed by transcription of target genes (99). 
In keratinocytes, IL-22 stimulates expression of the alarmins S100A8 and S100A9 that 
have been implicated in MDSC recruitment in other tissues (100–102). Further, IL-22 has 
been shown to induce the expression of various chemokines, CXCL2 (103), CXCL3 
(104), and CXCL5 (101), which aid in MDSC chemotaxis to various target tissues (105–
107). Indeed, IL-22 in other tissues has been shown to alter the immune milieu in favor of 
MDSC recruitment. Does Th22 and thus IL-22 presence in breast cancers ultimately 
support MDSC recruitment?  
Type 3 Immunity and Cancer:  
T Helper Cell 17 and  
Interleukin 17 
 
T helper cell 17. Th17 cells are a heterogeneous cell type that are similar to Th22 
cells in that they exhibit both pro-inflammatory or anti-inflammatory functions depending 
on the context. Pro-inflammatory, or pro-pathogenic Th17 cells are characterized by 
expression of IL-17A, IL-17F, IL-21, granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and IL-22; whereas anti-inflammatory, or non-pathogenic Th17 cells primarily 
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express IL-17A, IL-17F, and IL-10. Pathogenic Th17 are thought to be important drivers 
of various autoimmune diseases, while conversely, non-pathogenic Th17 are that to play a 
regulatory, immunomodulatory role in autoimmune prevention. The development of the 
pro- versus anti-inflammatory Th17 phenotype is dependent on the cytokine profile 
present during Th17 polarization. Absence of IL-23 drives non-pathogenic Th17 
differentiation while the presence of IL-23, IL-1b or TGF-b3 favors pathogenic Th17 
development (108, 109).  In carcinomas, the cytokine profile of Th17 resembles a non-
pathogenic phenotype that may assist in shaping a pro-tumor microenvironment.  
Not only are Th17 a heterogeneous population, but they are among the most 
‘plastic’ of Th cells in that Th17 may repolarize following recruitment to a target tissue. 
The most common repolarization events that Th17 undergo are reprograming to a Treg 
which may give rise to an IL-17+ Treg (110, 111), or reprogramming to a Th1 phenotype 
leading to an intermediate IFN-g+, IL-17A+ phenotype referred to as Th1/17 (108, 112, 
113). To our knowledge, the Th1/17 phenotype preferentially occurs by Th17 
repolarization, but this is not to say that Th1 reprogramming to Th17 via the Th1/17 
intermediate does not occur. Th17 cell presence in a solid tumor can also have pro- or 
anti-tumor effects, depending on the context of the cytokine milieu and tumor 
microenvironment. This duality likely stems from Th17 plasticity: in an anti-tumor 
scenario, Th17 can transdifferentiate to a Th1/17 IFNg+ producing cell to further promote 
Type 1 immunity (112, 114). Th1/17 may also support anti-cancer immunity by 
increasing TIL populations through the expression of CXCL9 and CXCL10 (115). In a 
pro-tumor state, Th17 may differentiate into a Treg, or even a Th2 cell phenotype, thus 
promoting immune suppression and ineffective Type 2 immunity (112).  Ultimately, Th17 
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repolarization toward a pro or anti-tumor phenotype is largely dependent on the cytokine 
profile provided by the tumor microenvironment. 
Blood and tumor Th17 populations have been associated with poor prognosis as in 
colorectal, pancreatic and hepatocellular carcinoma; however, ovarian cancer patients 
with elevated Th17 showed enhanced survival (114). In breast cancer patients 
specifically, increased numbers of Th17 have been associated with more aggressive 
subtypes including luminal B (HER2+ luminal) and triple-negative breast cancer 
(estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-
negative) (116). Th17 cells have been shown to promote the upregulation of tumor 
growth-stimulating CXCL1 (117), and they also express the CD39 and CD73 
ectonucleotidases, which hydrolyze ATP to adenosine (118). Extracellular adenosine has 
immunosuppressive functions; it acts to halt effector T cell functions while promoting 
differentiation of Treg. Thus CD39, CD73, and associated adenosine are now recognized 
as an immune checkpoint and coincidently, CD39 and CD73 are also highly expressed on 
MDSCs (119).  
Interleukin 17 ligand. While few studies have detailed the effects of Th17 cells 
on breast cancer, their hallmark chemokine IL-17 has been scrutinized extensively and 
predictably has been described as having both pro- and anti-tumor effects. On the pro-
tumor side, breast cancer cells exposed to IL-17 upregulate expression of CXCL8, 
MMP2, and MMP9, which drive tumor angiogenesis and tumor cell invasion into 
surrounding tissue (120). In the 4T1 mouse model of mammary carcinoma, knocking out 
IL-17 receptor heightened apoptosis and slowed tumor cell proliferation (121). 
Additionally, IL-17 has been shown to promote tumor growth and metastasis by 
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recruitment of neutrophils through CXCR2 chemokine ligands and IL-6 (114, 121). On 
the anti-tumor side, two studies have now identified IL-17 mediated inhibition of MDSC 
expansion. MDSC were found to be inhibited by IL-17 in three ways, it: 1) inhibited 
MDSC proliferation by suspending cells in G0/G1 of the cell cycle, 2) triggered MDSC 
apoptosis, and 3) stimulated further differentiation to a mature myeloid cell phenotype 
(122, 123).  
Interestingly, MDSC are thought to be immature cells arrested in an early stage of 
myeloid development, and while the stage of development is unclear, MDSCs have the 
potential to differentiate into mature myeloid lineages including (potentially anti-tumor) 
macrophage, neutrophils or dendritic cells (124, 125). Because of this differentiation 
potential, and the fact that very similar marker profiles are used to distinguish MDSCs 
from mature macrophage, neutrophils or dendritic cells; there is often confusion as to 
whether MDSCs or a mature myeloid cell is being identified. Preforming a functional T 
cell suppression is a good way to distinguish the difference between MDSC and other 
myeloid cells (126). Nonetheless, IL-17-stimulated MDSC differentiation seems to be in 
direct opposition to two studies where IL-17 mediated recruitment of neutrophils 
correlated with poorer breast cancer outcomes (127, 128). This may also be partly due to 
the multifaced neutrophil phenotypes where N1 neutrophils possess anti-tumor effects 
versus N2 neutrophils that have pro-tumor effects (129). Additionally, a high neutrophil-
to-lymphocyte ratio has been correlated in many studies as an indicator of metastatic 
potential and poor prognosis (130–134). Therefore, IL-17 stimulated MDSC-to-
neutrophil differentiation could, in fact, stimulate metastatic potential. Of course, the 
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question may be posed are neutrophils correlated breast cancer metastases or are these 
neutrophils truly just misidentified MDSC? 
Myeloid Derived Suppressor Cells  
in Cancer 
 
MDSCs have long been known to facilitate tumor progression, promote tumor 
resistance to therapy, and are generally associated with poor prognosis for cancer patients 
(10). MDSCs can be classified into two distinct subsets: monocytic (M-MDSC) and 
granulocytic or polymorphonuclear (PMN-MDSC). M-MDSC are more potently 
suppressive than PMN-MDSC, however, the PMN-MDSC population is observed to be 
more readily expanded in breast cancer patients. The most prominent forms of direct Th 
suppression associated with MDSC include: upregulation of reactive oxygen species 
(ROS), inducible nitric oxide synthase (iNOS) and oxidative NO production, arginine 
substrate depletion by arginase-1, and local release of inhibitory molecules such as 
prostaglandin E2 and adenosine (43, 119). Moreover, MDSC facilitate 
immunosuppression indirectly by TGF-β1 expression (135), which supports the 
production of Treg (43, 136).  
Many systemic growth factors have been implicated in the development and 
expansion of the MDSC population, with the most prominent candidates being 
macrophage colony-stimulating factor (M-CSF), GM-CSF, and IL-6 (137). For some 
time, M-CSF and GM-CSF were presumed to be necessary and sufficient to drive all of 
MDSC biology, suggesting that altering IL-6 expression alone would not significantly 
reduce MDSC development in the cancer setting (10). Recently, however, IL-6 has been 
shown to be involved in MDSC recruitment and may underlie the poor prognosis in many 
IL-6 overexpressing malignancies including breast cancer (138–140). In therapeutic 
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models, inhibiting IL-6 signaling in murine squamous cell carcinoma led to a reduction in 
MDSCs by initiating a shift toward anti-tumor type 1 IFN-γ production (141). 
Additionally, IL-6 further aids in type 3 Th polarization (31). Considering its role in 
cancer and other disease states, IL-6 has also become a sought-after therapeutic target in 
cancer due to the appearance of FDA approved tocilizumab in 2010 to treat autoimmune 
arthritis (142).  
Interleukin 6 and Clustered  
Regularly Interspaced  
Short Palindromic 
Repeats 
 
Interleukin 6. There are two types of inflammation- acute and chronic. Acute 
inflammation occurs when the immune system recognizes damaged tissue, but there is 
minimal damage or stimuli, so the acute inflammatory response mediated by neutrophils 
will initiate healing and resolve quickly. Chronic inflammation ensues when significant, 
prolonged exposure to inflammatory stimuli exists over months of time as would likely 
occur in cancer, autoimmunity, or sepsis. The persistent activation of adaptive and innate 
immune cells, coupled with continuous tissue repair and remodeling, leads to polarization 
of an immune response that is often initially correct but may progressively drift or change 
to actually further exacerbate inflammation (143).   
IL-6 is a pleiotropic cytokine that plays a role in the initiation of both acute and 
chronic inflammatory responses. Acutely, IL-6 is a major upstream regulator of acute 
phase, damage-response proteins (144). Chronically, IL-6 helps promote an adaptive 
immune response and further shapes and defines the innate immune response. IL-6 signal 
transduction begins when IL-6 ligand enables dimerization of the IL6R and gp130 
membrane receptors, which are coupled to a JAK/STAT signaling cascade, and IL-6 
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activation of STAT3 transcription factor is most notable (145). gp130 is ubiquitously 
expressed, while IL6R expression appears to be limited to hepatocytes, leukocytes, and 
megakaryocytes; however, IL-6 signaling is not limited to these few cell types. In a 
phenomenon known as IL-6 ‘trans-signaling,’ a metalloprotease specifically ADAM17 
(146)  cleaves IL6R from the cell surface freeing soluble IL6R that can stimulate cells 
expressing gp130- which would explain IL-6’s ability to signal systemically to a variety 
of tissues (145). In cancer, IL-6 plays a role in manipulating both immune landscape and 
tumor growth by promoting cell proliferation and survival through STAT3 activation 
(147).  
Although IL-6 was initially thought of as an anti-tumor cytokine due to its 
conventional role in initiating an acute inflammatory response (148), the prolonged, 
chronic expression of IL-6 appears to directly support the implementation and 
differentiation of pro-tumor immunity. For example, IL-6 directly polarizes Th mediated 
immunity away from an anti-tumor type 1 IFN-g Th1 response (149) toward a pro-tumor 
type 3 Th17 or Th22 phenotype (31). Moreover, chronic IL-6 expression in sepsis, cancer, 
autoimmune disease, traumatic injury and now obesity has been correlated with MDSC 
accumulation (139, 150–152). For some time, GM-CSF and M-CSF were solely credited 
with MDSC formation, with little attention paid to IL-6 (10). Indeed, M-CSF and GM-
CSF are important factors in the promotion of general myelopoiesis, but their expression 
alone does not account for the arrested development of the myeloid lineage that spawns 
MDSCs (10, 153).  
Indeed, it is the presence of chronic IL-6 signaling that prompts immature 
myeloid accumulation with a suppressive, MDSC phenotype. Prolonged IL-6 signal 
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transduction results in altered myelopoiesis within the bone marrow, which has been 
linked to suppression of SOCS3, which under steady state conditions feeds back to inhibit 
JAK/STAT activation. A decrease in SOCS3 allows for continuous phosphorylation and 
activation of STAT3 by chronic IL-6 stimulation, and it also promotes GM-CSF and M-
CSF signaling that further enhances myelopoiesis (139). 
However, there remain many unresolved questions in the interactions between IL-
6 and MDSCs. For example, how does chronic IL-6 affect myelopoiesis such that 
myeloid development is arrested at the ‘MDSC stage’? Does IL-6 affect myelopoiesis by 
systemic delivery of IL-6 to the bone marrow? Or are MDSCs suppressive when they 
leave the bone marrow, or do they require further ‘education’, i.e., prolonged exposure to 
IL-6 or splenic ‘education’ to become suppressive? Do MDSCs react to acute bouts of 
IL-6 expression, such as exercise or physical activity? Is this a concentration-, source 
specific- or simply chronic expression-dependent effect of IL-6 on MDSC? Further 
questions emerge regarding Th populations and chronic IL-6 exposure. Does chronic IL-6 
affect polarization to Th17 versus Th22? Is it possible that reducing tumor IL-6 increases 
an IFN-g mediated immune response? Does IL-6 affect Th17 and Th22 systemically or 
locally within the tumor? Is tumor IL-6 necessary for Th recruitment to the tumor? 
Clustered regulatory interspersed short palindromic repeats. Considering the 
significant number of questions circulating around about IL-6 listed above, we targeted 
IL-6 for knockout using CRISPR-Cas9 in the 4T1 model of mammary carcinoma. 
Clustered regulatory interspersed short palindromic repeats (CRISPR) were originally 
discovered as a bacterial adaptive immune system against bacteriophage virus infection. 
In short, bacteria store DNA sequence from previous viral encounters in between 
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clustered regulatory interspersed short palindromic repeats of DNA. These segments then 
get transcribed into RNA know as a guide RNA (gRNA) and loaded into a Cas 
endonuclease. gRNA loaded Cas seek out the specific viral DNA target and induce a 
double stranded break when proper base pairing is formed (154–156).  In 2013, the 
Zhang lab was the first to successfully take advantage of the CRISPR-Cas9 system for 
genome editing in eukaryotic cells. In eukaryotic cells, the principal is the same: a gRNA 
is designed for a gene of choice and is either 1) loaded directly into a Cas (Cas9 being the 
most common) or 2) coded into a plasmid containing Cas coding region. This is injected 
or transfected into a cell, then the Cas9 gRNA complex unwinds genomic DNA probing 
the entire genome for base pairing matches. Each Cas has a protospacer adjacent motif 
(PAM) requirement, which must be recognized in the adjacent strand to the gRNA target 
in DNA before cutting will occur. When a complete match occurs the Cas endonuclease 
induces a double stranded DNA cut. Once a double stranded break is induced the cell will 
repair DNA by non-homologous end joining, often leaving small insertions or deletions 
(157).Thus rendering a knock out of the particular target gene. 
Rationale for Study  
As alluded to above, the classical view of the MDSC suppressive activity is direct 
cell-to-cell inhibition of the effector cytotoxic and Th populations. This model of MDSC 
suppression has overshadowed other potential immune interactions, specifically the 
interplay between type 3 Th17 and Th22 cells (9). It is thought that solid tumors of 
epithelial origin benefit from recruitment of type 3 Th helper cells due to amplified levels 
growth and survival-promoting IL-22 and IL-17A. The chronic presence of these Type 3 
cytokines has been linked to tumor promotion as well as increased metastatic potential 
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(33, 76, 158). In addition, IL-6 is implicated in both MDSC recruitment and Th17/ Th22 
polarization (31, 139), yet few studies have logically linked these phenomenon and 
explored whether chronic expression of IL-6 may, in fact, elicit both MDSC and Type 3 
Th expansion in the context of mammary carcinoma (31, 139). 
These studies examine the response of canonical type 3 T helper populations: 
Th17, and non-canonical populations: Th22, in the 4T1 model of mouse mammary 
carcinoma. Additionally, we characterize the response of Th1/17, which are Th17 cells 
transiting to a Th1 phenotype and are an indicator of immune polarization toward an 
effective, anti-tumor type 1 immune response (159). The 4T1 model was chosen for this 
study because it is representative of a triple negative breast cancer that does not have high 
levels of TIL, with a low mutational load rendering it unresponsive to immune 
checkpoint therapy (160, 161). 4T1 cells had also been shown by others to elicit a 
pronounced myeloid reaction in the form of MDSCs (162). Our findings provide further 
insight into the interactions among MDSC and type 3 immune cells, as well as IL-6, in a 
murine mammary cancer model (Figure 1). These results may help clarify some of the 
failures of immunotherapies in human breast cancers and inform future attempts aimed at 
improving immune and other therapies.  
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CHAPTER III 
 
METHODS  
Mice and 4T1 Mammary Tumors 
4T1 cells were purchased from the ATCC (Manassas, VA) and cultured in RPMI 
1640 (ThermoFisher) supplemented with, 1% pen/strep, 2 mM L-Glutamine, 1 mM 
Sodium Pyruvate, 10 mM HEPES, 0.05 mM β-mercaptoethanol, and 10% (by volume) 
FB Essence (VWR), the latter which is a mixed serum supplement. To grow syngeneic 
mammary tumors, female BALB/cJ mice (The Jackson Laboratory, Bar Harbor, ME) 
between four to six weeks of age were inoculated with 1.0 x 104 4T1 cells. Cells were 
washed and suspended in 100 µL 1X HBSS (Ca2+/Mg2+ free, ThermoFisher) before 
injection through the nipple of the upper right mammary fat pad using an insulin syringe. 
Mice were monitored daily for availability of food and water and any signs or symptoms 
of peripheral infection or inflammation. Palpable tumors were routinely detected 2 weeks 
after injection and tumor sizes were monitored by calipers. Final tumor volumes were 
calculated by (volume=(3.14/6)width´length2)(163). On the day of tissue harvest, mice 
were euthanized by CO2 asphyxiation and tumors weighed. All animal procedures were 
performed according to the Institutional Animal Care and Use Committee protocol 
1906CE-RH-RM-22, (previously 1511CE-RH-RM-18) and 1702C-NP-M-20. 
Additionally, the 4T1 tumor time course study was conducted, and tissue harvested at 
days 0, 7, 14, 21, and 28 post injection time point (Figure 2). 
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Interleukin 6 Gene Knock-Out in 4T1 Cells 
The CRISPR/Cas9 system was used to create 4T1 cells deficient in IL-6 (4T1-
IL6-KO). Guide RNAs were designed with CRISPOR software (http://crispor.tefor.net/) 
to target exon 2 of the Mus musculus il6 gene (GenBank: M24221.1) at sequence 
TATACCACTTCACAAGTCGG. The gRNA oligos (Invitrogen) were annealed, 
phosphorylated, and cloned into the pX458 vector following the Zhang lab protocol 
(157). pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid # 
48138; http://n2t.net/addgene:48138 ; RRID:Addgene_48138) (Figure 3). A transfection 
protocol using Lipofectamine 3000 (ThermoFisher) was optimized for 4T1 at 50% 
confluency in 12 well dishes by growing cells overnight in a 100 µl of additive-free 
RMPI 1640 containing transfection lipid and plasmid. Lipid and plasmid volume 
remained the same as suggested in the ThermoFisher protocol. The vector includes a 
green fluorescent protein (GFP) reporter, thus GFP+ cells were single-cell sorted into 96-
well plates using a Sony SH800 Cell Sorter. Subclones were cultured and IL-6 deficiency 
Figure 2: 4T1 wild type time-course study. Wild Type 4T1 (4T1-WT) were injected 
into non-tumor bearing mice. Spleen, blood, bone marrow, and tumor were harvested 
on days 7, 14, 21 and 28 post 4T1-WT injection. Tissue was processed, stained, and 
analyzed by flow cytometry. Heathy non-tumor bearing mice were included as a 
control. Mice form palpable tumor day 14 after injection.  
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was verified by fixed-cell flow cytometry with IL-6 antibody (BioLegend, #504504) 
(Figure 3). Two independent subclones verified as IL-6 knockouts were pooled to create 
the 4T1-IL6-KO line used in these studies. 
 
Figure 3: pSpCas9(BB)-2A-GFP (PX458) vector. gRNA with sequence 
TATACCACTTCACAAGTCGG was cloned into pX458 vector. pX458 plasmid map 
shown here from Addgene (Addgene #48138). 
 
 
 
 
C 
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Tissue Processing 
Spleens were weighed, dissected, and dissociated using a rubber policeman in 500 
µL of 1X HBSS. Blood was collected from the chest cavity following a cut to the aorta 
and local heparin infusion. Blood was centrifuged at 0.2 rcf for 10 min and buffy coat and 
plasma transferred to fresh vials and any residual red blood cells lysed with ACK lysis 
buffer. Bone marrow was flushed from excised femurs and tibias using HBSS. Final 
tumor sizes were measured prior to excision, and tumors were weighed after excision and 
removal of extraneous tissue. Tumor tissue was minced and mechanically separated using 
a cell dissociation sieve fitted with a 100 µm mesh screen and resuspended in 1 ml 
HBSS. Cells were resuspended in Type IV collagenase (2mg/1mL) and DNase (0.1 
mg/mL; Worthington) and incubated at 37 oC rocking at 225 rpm for 1 hour. Remaining 
erythrocytes from various tissues were cleared with ACK lysis buffer (Quality 
Biological). 
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Figure 4: CRISPR/Cas9 knockout of IL-6 in the 4T1 cell line. Wild Type 4T1 
(4T1-WT) versus IL-6 knock out 4T1 (4T1-IL6-KO) expression of IL-6 via 
intracellular flow cytometry. (A) Histogram demonstrating relative fluorescence, and 
(B) Percent of total 4T1 that are IL-6 positive. (C) Total cells in a 4T1-IL6-KO tumor 
positive for IL-6. 
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Flow Cytometry and Antibodies 
Cells were stained in flow cytometry buffer: 0.5% BSA in Ca2+/Mg2+ free 1X 
Dulbecco’s PBS (ThermoFisher). Flow reagents and antibodies were purchased from 
Biolegend (San Diego, CA) unless stated otherwise. Fc block (101302) was used prior to 
staining with extracellular markers following the manufacturer’s protocol. Any surface 
marker staining was performed prior to fixation in fixation buffer (420801) per the 
manufacturer’s recommendation. For intracellular markers, prior to cell surface staining 
and fixation, cells were treated with 1X brefeldin A (420601) for 3-4 h at 37 oC to block 
intracellular protein trafficking. Cells were then stained for surface markers, fixed, then 
permeabilized with permeabilization buffer (421002), and finally stained for intracellular 
targets according to manufacturer’s protocols. Samples were analyzed using an Attune 
NxT cytometer (ThermoFisher); raw data were processed in FCS Express (De Novo 
Software). The biomarker profiles and antibodies used to define cell types in these studies 
outlined in Table 1 and 2. Example of flow cytometric gating strategy Figure 5A, B.  
 
 
 
 
 
 
 
Table 1: Cell biomarker profiles 
Cell Type Biomarker Profile  
M-MDSC CD11b+Ly-6G−Ly-6Chi 
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PMN-MDSC  CD11b+Ly-6G+Ly-6Clow 
Th CD3+CD4+ 
Th17  CD3+CD4+RORγt+IFN-γ−IL-17A+IL-22+/- 
Th1/17  CD3+CD4+RORγt+IFN-γ+IL-17A+IL-22+/- 
Th1  CD3+CD4+IFN-γ+RORγt-IL-17A−IL-22+/- 
Th22  CD3+CD4+IFN-γ−RORγt-IL-17A−IL-22+ 
 
Table 2: Antibodies and Catalog Numbers  
Biomarker Antibody Catalog Number 
CD3 100237 Biolegend 
CD4 100438 Biolegend 
IFN-γ 505806 Biolegend 
IL-22 516409 Biolegend 
IL-17A 506904 Biolegend 
RORγt 46698180 ThermoFisher 
MDSC antibody cocktail 77496 Biolegend 
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Figure 5:  Flow cytometry gating strategies. Representative samples of (A) MDSC and 
(B) Th gating strategies. Blood represented.  
 
 
 
 
 
 
 
 
 
 
Statistical Analysis 
All data are presented as mean ±SEM and statistical tests used α = 0.05. Grubbs’ 
test was used to identify any outliers. All multiple comparisons were calculated using 
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one-way ANOVA with Turkey’s multiple comparisons test. Single comparisons were 
calculated using Student’s t-test. A simple linear regression and Pearson’s correlation 
were used to assess the relationship between cell types in the 4T1-WT time course study 
for each of these regressions animals across all time points were included. A confidence 
interval (CI) of 95% is represented as well as Pearson r and r2 values, with significance 
set by α = 0.05. All statistical analyses were conducted in Prism 8 (GraphPad). R2 
(coefficient of determination) and r (Pearson correlation coefficient) values are used to 
predict the relationship between independent and dependent variables in a linear model. 
R represents the overall strength and direction of a correlation, while r2 is indicative of 
how well the data fit to a regression line. R values are measured from -1 to +1; 0 
indicating no relationship. R2 are measured from 0 to +1 while 0 indicates the model 
explains none of the variability (164).  
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CHAPTER IV 
 
RESULTS  
T Hepler Cell Immune Populations in Response to  
4T1 Wild Type Tumors 
 
Tumor and Spleen 
We assessed the Th immune response including type 1, type 3, and transitional Th 
populations in animals bearing 4T1 mammary tumors at 0 (no tumor control), 7, 14, 21 or 
28 days (d) after tumor cell injection. When we inject 104 4T1 carcinoma cells into the 
mammary gland of our BALB/c mice, small but palpable tumors form at the injection site 
by d 14 (Figure 6A, B). Others have also reported increased spleen size, or splenomegaly, 
in this model (165). Interestingly, in d 7 animals we observed a significant reduction in 
spleen mass relative to controls, but by days 21 and 28 the tumor-bearing animals show a 
pronounced increase in spleen size as has been reported elsewhere (Figure 6C). To our 
knowledge, this is the first report of this early reduction in spleen size in this 4T1 tumor 
model.  
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Figure 6: Tumor and spleen sizes in 4T1 tumor bearing animals. 4T1-WT 
carcinoma cells (104) were injected into the mammary gland of BALB/c mice and 
harvested at 0 (no tumor control), 7, 14, 21 or 28 d post injection. (A) Tumor volume, 
(B) tumor mass and (C) spleen mass were determined at the indicated times. Data are 
represented as mean ± SEM; n= 4-11 mice per time point. *p<0.05, **p<0.001, 
***p<0.001 and ***p<0.0001. 
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Total T Helper Cell Populations 
Various Th cell phenotypes were assessed in spleen, blood, bone marrow, and 
tumor at each time point. The percentage of total Th cells remained relatively unchanged 
in tumor, blood, and other peripheral tissues with modest increases detected in spleen and 
bone marrow at days 14 and 21, respectively (Figure 7A, B).  
Type 3 T Helper Cell Populations  
Within the total Th cell population, however, we observed dynamic changes in the 
Th cell subtype. In the spleen, the Th17 population increased significantly by d 7 post-
injection compared to no tumor controls and declined thereafter such that the percentage 
of Th17 recruited/remaining by d 28 was significantly lower than d 7. This same trend in 
Th17 recruitment was observed in the blood and bone marrow (Figure 7, G-H). Notably, 
unlike Th17, Th22 cells in peripheral organs were not expanded initially at d 7 compared 
to no tumor controls. Th22 increased significantly over time in blood compared to heathy 
controls (Figure 7I). In the tumors, Th17 and Th22 are present initially at d 14, Th17 
significantly decline by d 28 whereas Th22 significantly increase at d 28 compared to d 
14 tumors (Figure 7H, J). Due to the inverse pattern of Th17 and Th22 recruitment, we 
computed the Pearson correlation between Th22 and Th17 polarization over time. There 
was no correlation between Th22 and Th17 in the blood or bone marrow; however, there 
was a significant negative correlation (r2=0.14) in the spleen, and a significant positive 
correlation in tumors (r2=0.25; Figure 8A-D).  
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Figure 7: Th populations over time in 4T1-WT tumor bearing mice. Flow 
cytometric measurement of total Th, Th1, Th1/17, Th17, and Th22 in peripheral tissues 
(A, C, E, G, I) or tumors (B, D, F, H, J) at the indicated times. Data are represented 
as mean ± SEM and n= 4-11 mice per time point. *p<0.05, **p<0.001, ***p<0.001 
and ***p<0.0001.  
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T Helper Cell 1 Polarization 
Th1 recruitment was also assessed. The spleen was the only tissue where Th1 
remained statistically elevated compared to healthy animals (Figure 7C). In the blood, T-
h1 were significantly expanded at all times post injection consistent with a mobilization 
of this Th subtype. In bone marrow, Th1 were significantly elevated compared to control 
and d 28 tumor-bearing mice (Figure 7C). Although Th1 are present in the tumor, there 
was no statistical significance seen over time suggesting that increased circulating Th1 in 
the blood did not result in a pronounced infiltration of these cells into the tumor 
microenvironment (Figure 7D).  
We also examined correlations between Th1, Th17, and Th22 and found significant 
negative correlations between Th1 and Th17 in the spleen and tumor (Figure 8E, H), but a 
significant positive correlation in the bone marrow (Figure 8G). When assessing Th1 
versus Th22, there was a significant negative correlation between these two cell types in 
the tumor (Figure 8L). These findings suggest that in the spleen or tumor there is 
potential for polarization away from type 1 toward a type 3 Th phenotype. In addition, it 
may be that spleen and tumor are conducive to initial Th activation and polarization (or 
repolarization), which may explain the relationships in these tissues, but not in blood 
(Figure 8F, J).   
Transitional Type 1 to 3 T  
Helper Cell 1/17  
Populations  
 
Th1/17 were relatively unchanged in blood and bone marrow throughout the time 
course. However, in the spleen Th1/17 were significantly increased compared to d 0 at 
every time point except d 14 (Figure 7E). The same trend was not seen in the tumor. 
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Th1/17 were initially detectable in the tumor at d 14 but were then significantly reduced 
at d 28 (Figure 7F). Interestingly, the pattern of recruitment of Th1/17 and Th17 to the 
tumor were similar during the various time points. Due to the Th1/17 differentiation 
plasticity that exists between Th1 and Th17, we looked at Pearson correlations and found 
that Th1/17 and Th17 were positively correlated over time (r2=0.62, Figure 8P). However, 
no correlation was observed in peripheral organs (Figure 8, M-O). When examining 
Th1/17 and Th1 we saw significant negative correlations in the spleen (r2=0.19), blood 
(r2=0.36) and bone marrow (r2=0.76; Figure 7, Q-S) but a minimal relationship in the 
tumor (Figure 8T). These correlation patterns are consistent with differentiation away 
from the type I Th1 cells toward the type 3 Th17 phenotype. 
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Figure 8: Correlations among Th subsets in 4T1-WT tumor bearing mice. Pearson 
correlations between (A-D) Th17 and Th22 (E-H) Th17 and Th1 (I-L) Th17 and Th1 
(M-L) Th17 and Th1/17 (Q-T) Th1 and Th1/17 levels in spleen, blood, bone marrow 
and tumors in 4T1-WT tumor bearing mice based on data shown in Figure 7. Simple 
linear regression and 95% CI are included to help visualize relationships. *p<0.05, 
**p<0.001, ***p<0.001, ***p<0.0001, and ****p<0.00001  
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Myeloid Derived Suppressor Cell  
Expansion and Relationship to  
Type 3 T Helper Cell 17  
and T Helper Cell 22 
 
Myeloid Derived Suppressor Cells  
MDSCs were measured in the spleen, blood, bone marrow and tumor, and both 
M-MDSC and PMN-MDSC exhibited expansion in the peripheral organs, though each 
displayed a distinct pattern of MDSC expansion (Figure 9, A-C). In the spleen, MDSCs 
progressively increased over time, while blood MDSCs were not significantly elevated 
until late stage (d 28) of tumor development. In the bone marrow, MDSCs peaked early 
on at d 7, and then declined at later time points, however, they remained significantly 
elevated above baseline. Recruitment to the tumor differed between M-MDSC and PMN-
MDSC yet were both present by d 14 (Figure 9B, D). M-MDSC did not change 
significantly over time, whereas PMN-MDSC progressively increased in the 4T1 tumors.  
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Figure 9: 4T1-WT tumor-induced MDSC expansion. Flow cytometric 
measurement of (A) M-MDSC (CD11b+Ly-6G−Ly-6Chi) and (B) PMN-MDSC 
(CD11b+Ly-6G+Ly-6Clow) in response to 4T1-WT mammary carcinoma over time. 
Data are represented as mean ± SEM and n= 4-11 mice per time point. *p<0.05, 
**p<0.001, ***p<0.001 and ***p<0.0001. 
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Correlating Myeloid Derived  
Suppressor Cell and Type 3  
T Helper Cell 
 
 Due to a positive MDSC and type 3 Th correlation in other systems (lupus 
erythematosus, autoimmune encephalomyelitis, rheumatoid arthritis, and autoimmune 
arthritis, H. pylori infections, and colon cancer (9, 44, 78) suggesting that perhaps 
MDSCs may be directly stimulating the type 3 immune response, we wanted to determine 
if similar associations exist in mammary carcinoma. Again, we used Pearson’s 
correlations to compare the patterns of various Th cell types described in Figure 7 across 
the time course of MDSC proportions in Figure 9 (Figure 10). No significant correlation 
was observed in the spleen or tumor between MDSCs and any of the Th cell types. There 
were significant negative correlations in blood between Th17 and PMN- or M-MDSCs, 
r2=0.21 and r2=0.42 respectively (Figure 10J, N). In the bone marrow, we observed no 
relationship between Th22 and MDSC (Figure 10C, G). When looking at the correlation 
between Th17 and MDSC in bone marrow we saw a positive association between PMN-
MDSC and Th17 with r2=0.41 as well as M-MDSC and Th17 r2=0.67 (Figure 10K and O). 
Cumulatively this suggests that MDSC likely do not elicit type 3 Th in mammary cancer 
specifically in tumors. MDSC may, however, recruit Th17 in the bone marrow of 4T1 
tumor bearing mice. 
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Figure 10: Correlations between Type 3 Th and MDSC accumulation.  Pearson 
correlation assessing the association between Type 3 Th percentages shown in Figure 
7, and MDSC percentages shown in Figure 9. (A-D) Th22 and PMN-MDSC, (E-H) 
Th22 and M-MDSC, (I-J) Th17 and PMN-MDSC, and (M-P) Th17 and M-MDSC 
recruitment in the spleen, blood, bone marrow and tumor of 4T1 tumor-bearing 
animals. Simple linear regression included to visualize relationship and 95% CI are 
represented. *p<0.05, **p<0.001, ***p<0.001, ***p<0.0001, and ****p<0.00001. 
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The Role of Tumor Interleukin 6  
in Type 3 T Helper Cell  
Recruitment   
 
Following our initial time course study, we chose to knock out IL-6 using 
CRISPR-Cas9 (Figure 3, (166)) to generate a 4T1 IL-6 knock out (4T1-IL6-KO) cell line. 
Unlike other studies in which IL-6 is knocked out in the entire animal (167), this 
approach narrows the IL-6 deficiency to the 4T1 tumor cells. Indeed, in whole tumors  
there are still stromal and immune cells recruited that produce IL-6 (Figure 4). We did 
not observe a significant difference in tumor volume over time or day 28 tumor mass 
between 4T1-WT and 4T1-IL6-KO tumors (Figure 11A-B). Day 28 spleen mass was 
significantly elevated in 4T1-IL6-KO compared to healthy no tumor controls (Figure 
11C). 
Figure 11: 4T1-WT vs. 4T1-IL6-KO tumor bearing mice measurements of tumor 
and spleen. (A) 4T1-WT and 4T1-IL6-KO tumor volumes were measured over the 
course of progression. 4T1-WT and 4T1-IL6-KO tumor volumes were not statistically 
significant at any time point. (B) Final tumor mass comparing 4T1-WT and 4T1-IL6-
KO tumors at a day 28 post injection time point. Tumors were not statistically 
different in mass. Measurements in (A) and (B) should likely be repeated as many 
animals developed two tumors and is likely a result of miss injection. (C) Spleen mass 
at a day 28 time point. Healthy non-tumor bearing spleens included for reference. 
4T1-IL6-KO spleens have a significantly greater mass than 4T1-WT and healthy 
controls. ANOVA with Tukey’s multiple comparisons. Data are represented as means 
± SEM and n= 6-11 mice. *p<0.05, **p<0.001, ***p<0.001 and ***p<0.0001.  
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Based on the results obtained in the earlier time course, we decided to look at type 
3 accumulation at the d 28 time point with the 4T1-IL6-KO cells. While 4T1-WT tumors 
significantly reduced Th17 at d 28 in the periphery compared to healthy controls, Th17 
remained unchanged with the 4T1-IL6-KO tumors in all peripheral organs (Figure 12A). 
Th22 were expanded in blood and bone marrow of 4T1-WT mice yet remained 
unchanged in spleen and blood in 4T1-IL6-KO. In the bone marrow, Th22 were 
significantly reduced in 4T1-IL6-KO compared to 4T1-WT tumor-bearing mice (Figure 
12C). In tumors, Th17 are expanded (Figure 12B) and Th22 are significantly reduced 
(Figure 12D) in 4T1-IL6-KO compared to 4T1-WT. These data suggest that Th17 are 
affected by tumoral IL-6 local to the tumor. This observation may be in line with the 
tumor microenvironment ability to re-polarize the type of Th immunity (68). We saw little 
systemic effect on Th17 due to the reduction of IL-6 but we see a significant reduction of 
Th22 in the bone marrow. This observation may suggest that 4T1-IL6-KO have a lower 
metastatic potential to the bone marrow than 4T1-WT due to the reduction in Th22 in the 
bone marrow. 
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Figure 12: Tumor IL-6 affects type 3 Th recruitment to the tumor at day 28. Day 
28 recruitment of (A-B) Th17 and (C-D) Th22 in healthy non-tumor controls, 4T1-WT 
and 4T1-IL6-KO in periphery and tumors of tumor bearing mice. 4T1-IL6-KO is 4T1 
specific IL-6 knockout. Statistical significance was measured using one-way ANOVA 
with Tukey’s multiple comparisons or students t-test. Data are represented as means ± 
SEM and n= 4-11 mice. *p<0.05, **p<0.001, ***p<0.001 and ***p<0.0001 
 
  
49 
Effects of Tumor Interleukin 6 on 
T Helper Cell 1, T Helper Cell  
1/17, T Helper Cell, and  
Myeloid Derived  
Suppressor Cell 
 
 We also examined Th1/17, Th1, total Th, and MDSC recruitment in the 4T1-IL6-
KO model as these cell populations could be viewed as indicators of a ‘pro-
immunotherapeutic’ environment assuming tumor IL-6 could be similarly depleted in the 
clinic. In 4T1-IL6-KO tumor bearing mice, the percentage of total Th cells remained 
unchanged in spleen and bone marrow but were significantly increased in blood and 
tumors (Figure 13). We found that Th1/17 were significantly increased in blood and 
tumor in 4T1-IL6-KO compared to 4T1-WT tumor bearing mice. Compared to 4T1-WT 
where Th1/17 polarization was readily apparent, in 4T1-IL6-KO tumors and Th1/17 were 
significantly increased (Figure 14A). Th1 significantly increased in the spleen and 
significantly decreased in the blood in 4T1-IL6-KO tumor bearing mice compared to 
4T1-WT counterparts suggesting that removal of tumoral IL-6 may be therapeutically 
beneficial (Figure14B).   
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Figure 13: Tumor IL-6 depletion increases tumor-infiltrating Th Cells. Th cell 
recruitment at d 28 by 4T1-WT and 4T1-IL6-KO tumors. Data are represented as 
means ± SEM and n= 4-11 mice. *p<0.05, **p<0.001, ***p<0.001 and ***p<0.0001 
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Figure 14: Depleting tumor IL-6 increases Th1 and Th1/17 cells. Recruitment at d 
28 of (A) Th1/17 and (B) Th1 in response to 4T1-WT vs. 4T1-IL6-KO tumors. Data 
are represented as means ± SEM and n= 4-11 mice. *p<0.05, **p<0.001, ***p<0.001 
and ***p<0.0001 
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Removing tumor cell-derived IL-6 led to a significant reduction of both M-MDSC 
and PMN-MDSC in all peripheral organs compared to 4T1-WT tumors (Figure 15A, C), 
further supporting the idea that IL-6 promotes MDSC expansion and that blocking 
systemic IL-6 signaling could prove beneficial to cancer patients. However, only tumor 
infiltrating M-MDSC were significantly reduced in 4T1-IL6-KO tumors (Figure 15B), 
whereas PMN-MDSC remained unchanged (Figure 15D).    
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Figure 15: Tumor IL-6 depletion reduces both M-MDSCs and PMN-MDSCs. (A-
B) M-MDSCs and (C-D) PMN-MDSCs in healthy controls, 4T1-WT and 4T1-IL6-
KO in periphery and tumors of tumor bearing mice. 4T1-IL6-KO a 4T1 specific IL-6 
knockout. Data are represented as means ± SEM and n= 4-11 mice. *p<0.05, 
**p<0.001, ***p<0.001 and ***p<0.0001.  
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CHAPTER V 
DISSCUSSION  
4T1 Tumor Time-Course Studies 
Implications of Type 3 Polarization 
in Breast Cancer 
 
Our results show that Type 3 Th are dynamically recruited over time in response 
to mammary carcinoma. Th17 were recruited initially in spleen, blood, bone marrow, and 
tumor and diminished at later time points. The opposite was seen of Th22, which were 
recruited to the tumor at later timepoints. Due to the dynamic nature of type 3 Th in 
response to mammary carcinoma, our findings indicate that the efficacy of clinical 
checkpoint inhibitors could be substantially diminished by enhancing type 3 immunity. It 
remains to be seen whether checkpoint therapy is able to enhance a pro-tumor Th2, Th17 
or Th22 response as opposed to increasing anti-tumor Th1 or cytotoxic T cells, further 
experiments are necessary to answer this question.  In theory, if type 3 Th are amplified, it 
is possible that a negative immune response promoting tumor growth may persist with 
little amplification of type 1 immunity (68, 168). Indeed, clonal expansion followed by 
the polarization of type of immunity is possible following checkpoint inhibitor treatment, 
however, it remains to be seen what antigen these T cells recognize. It may be that they 
do not recognize tumor specific neoantigen displayed on MHC are merely bystanders. 
Checkpoint inhibitor-stimulated expansion of  Th22 may be detrimental to the 
patient due to the polarization away from Type 1 immunity, Th22 may also facilitate 
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metastasis in high grade breast cancer via IL-22 (81, 97). Thus, amplifying a Th22 
population in breast tumors may increase metastatic potential. The 4T1 model is 
representative of a high-grade mammary tumor (160, 161), which our data demonstrates 
robust Th22 recruitment as time progresses. Future studies using this, and similar models 
should be carried out to elucidate the potential effects of Th22, and by extension IL-22, 
on tumor and metastatic burden. 
Are T Helper Cell 17 and T Helper  
Cell 22 Different Type 3  
Subtypes? 
 
 Historically there has been debate as to whether Th17 and Th22 should be 
classified as distinct Th subsets (31). Our data suggest that Th17 and Th22 are inversely 
correlated in the spleen but directly correlated in the context of a metastatic tumor (Figure 
8 G and I). The spleen is a secondary lymphoid structure where Th subset polarization 
occurs. Based on the negative correlation we observed between Th17 and Th22 in the 
spleen, we suggest that Th17 and Th22 are unique functional subsets due to the ability to 
be maintained in an opposing nature. A positive correlation of Th17 and Th22 suggests 
the potential repolarization of Th17. Whether the reprogramming of Th17 to a Th22 
phenotype is possible remains unclear and the present data underscore the need for 
additional focus on IL-22 in promoting metastasis (169). Moreover, IL-22 is known to 
promote wound healing in the skin and gastrointestinal tract, suggesting that this cytokine 
may enhance a breast tumor microenvironment and provide aid for the growth of 
malignant cells (33, 170). 
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Potential Impacts of Myeloid  
Derived Suppressor Cells on  
Checkpoint Inhibitor  
Therapy 
 
The timing of checkpoint administration may be important as MDSC presence 
varies over time. Here, following tumor injection, PMN-MDSC and M-MDSC are 
induced early in the bone marrow but are not significantly elevated in blood and spleen 
until days 21 and 28 respectively. Early expansion followed by the reduction of MDSC in 
the bone marrow suggests splenic takeover of the maintenance of MDSC (Figure 9A and 
B). Early expansion of MDSC in the bone marrow, compared to other tissues is logical 
because MDSC are of the myeloid lineage, and myelopoiesis occurs in the bone marrow. 
It is, however, interesting that this increase in MDSC production occurs day 7 before a 
palpable tumor is detected suggesting early remodeling of immune tissue. A similar 
phenomenon is seen in the spleen at day 7, spleen mass is significantly lower than non-
tumor bearing controls which may suggest immune remodeling of the spleen prior to an 
enlarged mass (Figure 6C). Understanding the pattern of MDSC recruitment may serve as 
an additional parameter to determine the stage of tumor progression (43).  
 When evaluating the relationship between MDSC recruitment and Th17 it was 
found that there was a positive correlation in the bone marrow but a negative correlation 
in the blood (Figure 10J, N, K, and O). It may be possible that MDSC are capable of 
promoting Th17 responses before achieving full suppressive capacity. These data may 
suggest that when MDSC are first generated in the bone marrow they may not have 
acquired suppressive capacity. Thus, are able to promote Th17. While this is a stimulatory 
response, in the context of a metastatic tumor this is still negative as it would deplete the 
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necessary type 1 immune components necessary to mitigate tumor progression. Future 
studies evaluating the suppressive capacity of MDSC in the bone marrow over time 
following 4T1 mammary tumor injection are needed to support this claim. Still, this 
finding is in line with research in rheumatoid arthritis where MDSC promote Th17 
responses but are not able to suppress effector Th to halt an autoimmune reaction (9). 
Further, there were no significant correlations between MDSC and Th22 in the bone 
marrow and blood. This is more evidence suggesting that Th17 and Th22 should be 
regarded as different cell types, which may have unique functional relevance in the 
context of breast cancer. 
Polarization to Type 1 Immunity  
In addition to Th17, Th22, and MDSC recruitment in 4T1 mammary carcinoma, 
we assessed the recruitment of Th1/17 as a potential indicator of polarization to anti-
tumor type 1 immunity. The Th17 phenotype has been shown to be more plastic than the 
Th1 phenotype (112). Due to this, it is thought that Th1/17 are transiting away from Th17 
toward the Th1 phenotype (112) as opposed to the reverse. Our data support that previous 
work. We see that there is a significant positive correlation between Th1/17 and Th17 in 
the tumor across all time points. This suggests that when there are more Th17 present 
there is also a greater chance of detecting Th1/17. Further, there was no correlation 
observed between Th1/17 and Th17 in spleen, blood, or bone marrow indicating that the 
tumor microenvironment might play a unique role in the re-polarizing immune response. 
In the spleen, blood, and bone marrow, when comparing Th1/17 accumulation to Th1 we 
see a significant negative correlation. This event suggests once again that Th1/17 likely 
occur when Th1 polarization is low, indicating the potential to transition from type 3 to a 
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type 1 immune response. Additionally, if Th1/17 are transiting towards Th1 eventually 
you would expect the number of Th1 to increase. It is possible that a complete 
repolarization of Th1/17 is dependent on tumor specific milieu of cytokines and should be 
evaluated further. Understanding the conditions in which Th1/17 are likely to be 
amplified over Th17 following checkpoint therapy may prove to be therapeutically 
beneficial. 
Despite Th1/17 generation, which indicates that repolarization of Th17 into Th1 
may be possible it is still possible polarization away from type 1 to type 3 immunity. 
When evaluating the recruitment of type 1 and type 3 Th we saw significant negative 
correlations between both Th1 and Th17, and Th1 and Th22 in the spleen and tumor. This 
may indicate that there is potential for polarization away from type 1 towards a type 3 Th 
phenotype in mammary carcinoma given the proper stimulation of cytokines from the 
tumor microenvironment. We did not examine which population of Th cells (Th1 or Th17) 
were actively undergoing clonal expansion, however, Th17 is to be a more plastic Th 
phenotype as it is easily repolarized by the target tissue, such as a tumor (112). Due to 
this, we speculate that Th1/17 generation likely originates from a Th17, not a Th1. 
Tumor Interleukin 6 Studies 
Following our time course study using 4T1-WT tumor bearing mice, we focused 
on the effects of tumor-derived IL-6. IL-6 was targeted in this study for two reasons: 1) it 
acts as a broad pro-tumor cytokine, and 2) the presence of already clinically approved 
tocilizumab to target IL-6 signaling in rheumatoid arthritis (142). IL-6 promotes 
tumorigenesis by facilitating immune suppression, Th polarization away from type 1 
immunity and promoting angiogenesis (171). Further, IL-6 facilitates MDSC 
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development and type 3 Th polarization (30, 139). We used CRISPR to knock out IL-6 in 
the 4T1 cell line (4T1-IL6-KO) and compared Th17, Th22, Th1/17, and MDSC responses 
to changes in IL-6. When assessing Th17 and Th22 in the 4T1 tumor IL-6 knockout we 
found that IL-6 acts differently on Th17 and Th22. In the tumor, Th17 are expanded 
whereas Th22 are significantly reduced when the tumor source of IL-6 is removed. IL-6 is 
a key cytokine in fate determinate of both Th17 and Th22 lineage (31), but it has been 
thought that TGF-β1 is the major player in determining Th17 or Th22 polarization. TGF-
β1 presence drives Th17 polarization while inhibiting Th22 formation, while IL-6 is 
necessary but not sufficient to discriminate between these lineages. Our data suggest that 
there is an IL-6 concentration-dependent mechanism of Th22 or Th17 skewing, which 
should further be evaluated as there is currently little information on differential 
expression of IL-6R or IL-6R function on these cell types.  
Additionally, the reduction of tumor resident Th22 may be therapeutically 
beneficial due to the link between IL-22 growth and metastasis in other types of cancer 
(80). It remains unclear whether an increase of Th17 in this context would lead to pro or 
anti-tumor immunity. Specifically, this is because Th17 are a plastic subset of Th cell and 
their phenotype may be easily manipulated by the cytokine profile of the tumor 
microenvironment, thus they may remain pro-tumor Th17 or repolarize into tumor 
promoting Treg or tumor mitigating Th1 (108, 110, 112). 
Moreover, a significant increase in Th1/17 was observed alongside Th17 increase 
in the 4T1-IL6-KO tumor compared to 4T1-WT. Further supporting the notion that these 
cells are transitioning from Th17 to Th1 phenotype. Th1/17 were significantly elevated in 
the blood of 4T1-IL6-KO tumor bearing animals compared to 4T1-WT. The increase of 
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anti-tumor IFN-γ positive Th1/17 in the absence of tumor IL-6 suggests that IL-6 is a 
logical therapeutic target to accompany checkpoint immunotherapy.  
Additionally, tumor localized IL-6 should be investigated as a therapeutic target 
in this setting, because we observed a significant increase in total Th cells present in 4T1-
IL6-KO tumors as well as blood compared to 4T1-WT tumor-bearing animals. In 
addition, we observed a statistically significant reduction in M-MDSC across all tissues 
including tumor and a significant reduction in PMN-MDSC in all peripheral organs. 
Indeed, this was our initial prediction and impetus for the IL-6 portion of the study. 
Reducing MDSC accumulation in the periphery as well as in the tumor has been shown 
to bolster T cell-mediated immunotherapy (172). Additionally, the effects of IL-6 on 
extramedullary hematopoiesis (EMH) should be considered. 4T1 tumors are known to 
initiate extramedullary myeloid hematopoiesis in the spleen and liver of tumor bearing 
mice (137). Despite the decrease of MDSC in the spleen, we saw spleen masses were 
significantly increased in 4T1-IL6-KO compared to 4T1-WT tumor bearing mice (Figure 
11C). This may suggest that splenic EMH is increased in the absence of tumor IL-6 but 
allowing for the maturation of myeloid cells and potentially extramedullary lymphoid cell 
hematopoiesis. Additionally, in our 4T1-WT time course study, we observed MDSC 
expansion at d 7 in bone marrow accompanied by a significant decrease in splenic mass. 
In subsequent days MDSC in the bone marrow decreased while spleen size and MDSC 
accumulation in the spleen increased. This suggests that there is a delay in splenic EMH 
and the ability for splenic takeover of MDSC production over bone marrow derived 
MDSC. This raises further questions about when and how MDSC acquire suppressive 
capacity. 
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In our model knocking out IL-6 in 4T1 cells did not significantly reduce total IL-6 
in the tumor (Figure 4C), and we suspect this is due to infiltrating immune and stromal 
cell and systemic ability to produce IL-6 is intact, despite this we observed a significant 
impact on the local and systemic immune environment. Thus, we propose that a reduction 
in IL-6 from the tumor may be sufficient to alter the immune landscape. Although we 
saw positive anti-tumor alterations in immune response when eliminating tumor IL-6, it 
is important to further investigate whether the local source of IL-6 is important for this 
reduction or whether these systemic responses occur in a concentration dependent 
manner.  
Conclusion and Summary 
 In sum, this study demonstrated that there is a dynamic pro-tumor type 3 immune 
response in reaction to 4T1 mammary carcinoma (Figure 16). These data demonstrate the 
ability for breast tumors to polarize away from an anti-tumor type 1 immunity toward a 
type 3 response, highlighting that it might be possible for checkpoint therapy to amplify 
the wrong immune response. This has not been adequately explored, warranting future 
research into the impact of immune polarization on checkpoint efficacy. Furthermore, the 
effects of tumor-derived IL-6 on the tumor and peripheral immune landscapes were 
explored. It was found that knocking out tumor IL-6 significantly increased tumor 
infiltrating Th cells, significantly increased IFN-g producing Th1/17, and reduced MDSC 
recruitment (Figure 16). These results demonstrate that IL-6 should be considered a 
therapeutic target in select circumstances where aberrant type 3 immune skewing is 
involved, which may better facilitate an initial, appropriate anti-tumor immune response. 
Indeed, IL-6 may serve as a therapeutic target for the above reasons but IL-6 is necessary 
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to initiate an immune response. Lack of IL-6 has been shown to lower lymphopoiesis and 
poor infiltration of immune cells into sentinel lymph nodes. Due to these collective 
observations, the concentration of IL-6 will likely be important if implementing anti-IL-6 
therapy (173).  
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✓ 
IL-6 minimal, ?  
✓ 
Figure 16: Summary of interactions between 4T1 tumor cells, type 3 Th, and 
MDSCs; that are mediated by interleukin IL-6. In this study, we demonstrated that 
both Th17 and Th22 are dynamically recruited in the 4T1 tumor model of mammary 
carcinoma. Tumoral IL-6 plays a role in the formation of MDSC as removal lead to a 
systemic reduction in MDSCs. Tumor derived IL-6 was important to type 3 Th locally 
to the tumor but this effect was minimal, and possibly aids in repolarization of Th 
immunity. Additionally, total Th were expanded in the tumor when IL-6 was knocked 
out of the 4T1 cells. The connection between MDSC and type 3 Th has yet to be 
determined in mammary carcinoma. 
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Future Studies and Questions 
 
Myeloid Derived Suppressor Cell  
and Type 3 Immunity  
 
 Our data suggest that in the context of 4T1 mammary carcinoma there is not a 
relationship between MDSC recruitment and type 3 Th polarization. I make this 
assumption because type 3 Th and MDSC recruitment do not appear in lockstep with one 
another. Further studies evaluating whether or not this conclusion is accurate should be 
done. Additionally, a study should be done to reveal when MDSC achieve suppressive 
capacity, both in a time course setting and at the level of tissue specific MDSC. A study 
like this may reveal why we observed a positive correlation between Th17 and MDSC in 
the bone marrow of tumor-bearing mice; MDSC may be able to promote Th17 
polarization before they achieve suppressive capacity. MDSC have been shown to 
produce high levels of TGF-b1 (9), which in turn may drive a Th17 phenotype over a 
Th22 phenotype. This may be why we saw a positive correlation between presumably 
pre-suppressive MDSC and Th17 in the bone marrow and not between MDSC and Th22. 
Additionally, it would be interesting to assess the link between MDSC, Th17 and mast 
cells in a mammary carcinoma setting. The rationale here being TGF-b1 high-producing 
MDSC have been shown to promote mast cell activation. Mast cells upon TGF-b1 
challenge have been shown to secrete high levels of IL-6 (26), which has the potential to 
promote both MDSC and Th17 (9).  
T Helper Cell 17 and Mammary  
Carcinoma 
 
We found that Th17 are recruited at early time points in response to 4T1-WT 
tumors and then are reduced over time. I think in the future it would be interesting to 
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evaluate why we see this reduction of Th17. Is it possible that Th17 are initially polarized 
but following migration to the tumor they are driven into a Treg phenotype? Additionally, 
is it possible to capitalize on this early Th17 response and completely repolarize Th17 to 
tumor fighting Th1 help? 
Interleukin 6 and Checkpoint  
Immunotherapy  
 
In this study, the main immunological benefits found by removing tumor IL-6 
were the increase of tumor infiltrating Th and the reduction of MDSC. Lack of TIL and 
the recruitment of MDSC are thought to be major contributors to the failure of 
immunotherapy treatment in solid tumors. I propose that adding an IL-6 neutralizing 
antibody may increase the efficacy of checkpoint inhibitor therapy function. This 
combination has not yet been evaluated and should be considered for future studies. 
Additionally, it would be interesting to look at the polarization of Th immunity under the 
influence of checkpoint therapy as well as analyze the interactions between activated Th 
and their antigen in a mammary carcinoma setting.  
Study Limitations 
 Throughout the course of this study, we acknowledge the following limitations. In 
our flow cytometric panel, we did not include markers that allowed us to identify Th2, 
cytotoxic T cells or Treg. This meant that we were unable to evaluate changes to these cell 
populations. Most importantly, however, we are unable to say for certain whether the Th 
populations we evaluated fall into a Treg or effector Th category. Despite this, I argue that 
polarization of Type of immunity meaning the alteration in the tumor immune 
microenvironment and thus cytokine profile released by total Th may shape the outcome 
to immunotherapy treatment. 
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           Additionally, this research was only conducted using one model of mouse 
mammary carcinoma. Due to this, we do not know if similar results will be observed in 
other models of solid tumors, such as the B16 melanoma in C57/BL6 mouse. Another 
limitation arises when evaluating the 4T1-IL6-KO line. 4T1-IL6-KO were derived from 
two single knockout 4T1 clones. This presents a unique situation where there is not an 
exactly matched 4T1-WT control. Presumably, before using CRISPR to knock out IL-6 I 
could have started 4T1-WT colonies from a signal cell and used this to knockout IL-6 
and saved some as controls. Indeed, this was an option, but we decided not to proceed, 
because each colony would be cultured separately for a number of passages, which 
invariably introduces clonal divergence. 
           Lastly, I would like to state that I myself did not perform a functional suppression 
assay on MDSC in our model of 4T1 mammary carcinoma. However, this phenomenon 
has been reported extensively in the literature (10). Additionally, Jacob Garritson, a 
member of our laboratory performed MDSC T cell suppression assays from this model, 
and he observed that MDSC were indeed suppressive at the day 28 time point (work 
currently in peer review).
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APPENDIX B 
 
ANIMAL VITAL STATISTICS  
 
 
 
Figure 17: Female mouse body mass before injection and at day 28 post injection. 
Mass of (A) 4T1-WT and (B) 4T1-IL6-KO tumor bearing mice before injection and at 
day 28 post injection. Mice received tumors at 6-8 weeks old and were euthanized around 
10-12 weeks old. This weight gain is expected since the average weight of a healthy 6-8-
week-old female mouse is about 18g and of a 10-12-week-old female mouse is on 
average 21g. Data are represented as means ± SEM and n= 4-11 mice. *p<0.05, 
**p<0.001, ***p<0.001 and ***p<0.0001. 
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APPENDIX C 
 
CLUSTER OF DIFFERENTIATION 40+ T 
 HELPER CELLS IN 4T1 MAMMARY  
CARCINOMA 
 
Background 
 
Classically, CD40 is thought of as a costimulatory molecule expressed on 
professional APC such as dendritic cells and B cells, and its ligand CD40L is expressed 
on activated Th.  CD40 is not classically thought of as expressed of Th cells. In dendritic 
cells, the CD40/CD40L signaling axis is essential for dendritic cell survival and 
differentiation. Arguably, more importantly, CD40L+ effector Tfh interact with CD40 on 
B cells to facilitate immunoglobin class switching. When CD40L is rendered functionally 
impaired, Tfh help of B cell class switching is not achieved and hyper IgM syndrome is 
observed (174). Hyper IgM is characterized by increased serum IgM and insufficient 
levels of IgG, IgA, and IgE, thus and chronic risk of pathogenic infection (175).  
Despite the notion that CD40 is classically restrictively expressed on APC while 
CD40L is largely expressed on T cells and not CD40, the Wagner lab at Anschutz 
Medical Campus in Denver have recently classified a subset of pathologically active T 
cells that express CD40, which they have entitled Th40. The Wagner lab has identified 
Th40 or CD40+ Th in experimental autoimmune encephalomyelitis and in Type 1 diabetes. 
In both of these autoimmune diseases, their results indicate that CD40+ Th are 
pathologically active and drive these autoreactive immune responses (176–179). After 
seeing this work presented at the AAI in 2019, naturally we were curious if this 
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particularly autoreactive Th40 subset was present in our 4T1 model of mammary 
carcinoma. If so, it may be of therapeutic benefit to enrich an autoreactive CD40+ Th in 
order to improve immunotherapeutic efficacy in breast cancer. To our knowledge, this is 
the first study to evaluate CD40+ Th recruitment in mammary carcinoma.  
Research Questions 
Q1  Are CD40+ Th cells recruited in 4T1-WT Tumor bearing mice?  
 
Q2  Are CD40+ Th cells affected by tumor IL-6?  
 
Methods 
 
The same methodology was utilized as in the thesis proper, however, with the 
addition of a CD40 (BioLegend 124631) antibody to the Th cell flow cytometric panel. In 
short, a time course study was performed with 4T1-WT tumors evaluating CD40+ Th 
recruitment in spleen, blood, bone marrow and tumor at days 0, 7, 14, 21, and 28 post 
injection time point. Following this a day 28 time point was used to evaluate the effects 
of tumor IL-6. This was accomplished through CRISPR/Cas9 knockout of IL-6 
generating 4T1-IL6-KO cells. CD40+ Th were evaluated in 4T1-WT and 4T1-IL6-KO in 
spleen, blood, bone marrow and tumor. All data are presented as mean ±SEM and 
statistical tests used α = 0.05. All multiple comparisons were calculated using one-way 
ANOVA with Turkey’s multiple comparisons test. Single comparisons were calculated 
using Student’s t-test. 
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Results and Discussion 
Cluster of Differentiation 40+ T  
Helper Cell in 4T1 Wild  
Type Time Course  
 
CD40+ Th were detected in the spleen, blood, and bone marrow of both healthy 
and tumor-bearing mice (Figure 18A).  This was interesting because CD40+ Th have 
largely been ignored but are present in high numbers in a healthy mouse. CD40+ Th 
remained unchanged following tumor injection in the spleen and bone marrow but were 
significantly elevated at day 14 in blood compared to no tumor controls and day 28 tumor 
bearing controls (Figure 18A). CD40+ Th were found in the tumor; however, we saw that 
they decreased day 21 to day 28 in 4T1-WT tumor bearing mice. CD40+ Th are thought to 
be an auto-reactive Th (178, 179), which means that Th40 cells may have the potential to 
provide anti-tumor immunity to the host. Due to this, we evaluated the particular Th 
subset of CD40+ Th over time (Figure 18C-J). We found that the majority of CD40+ Th 
seemed to be either a Th1 phenotype or a Th17 phenotype (Figure 17C-D and G-H). The 
phenotype of CD40+ Th may be important when evaluating how CD40+ Th may provide 
an autoreactive or anti-tumor phenotype. In autoimmunity autoreactive Th are generally 
pathologically active Th17, however, some are Th1 (180). In the case of CD40+ Th the 
autoreactive phenotype is a mix between Th1 and Th17 suggesting these cells may be able 
to provide anti-tumor immunity (177). However, at this time we do not know the 
functional significance of CD40 expression on Th cells. Additionally, CD40+ Th that are 
Th17 decreased over time in the spleen and blood, which followed the trend of total Th17 
over time in 4T1-WT tumors. CD40+ Th that are Th22 were significantly increased at day 
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28 in the spleen compared to no tumor bearing mice, which directly opposed the 
depletion of CD40+ Th that are Th17.   
Cluster of Differentiation 40+ T  
Helper Cell and Tumoral  
Interleukin 6  
 
In the 4T1-IL6-KO tumor bearing mice, CD40+ Th are significantly increased in 
the spleen blood and bone marrow compared to 4T1-WT tumor bearing mice (Figure 
19A). Indeed, this may be a consequence of total Th increase in 4T1-IL6-KO compared to 
4T1-WT tumor bearing animals, however, if CD40+ Th are more auto-reactive this 
increase may be therapeutically beneficial. Additionally, we evaluated Th subset that 
were CD40+ Th (Figure 19B-E). 
Future Directions 
The functional importance of CD40 expression on Th has yet to be elucidated. In 
fact, the idea that CD40 may be expressed on Th has largely been ignored with the 
exception of the Wagner Laboratory. Uncovering functional significance of CD40 
expression on Th would be very interesting given that Th40 have been identified as more 
autoreactive than CD40- Th cells.  
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Figure 18: CD40+ Th expansion over time in 4T1-WT tumor bearing mice. Flow 
cytometric measurement of (A) total CD40+ Th in periphery (B) total CD40+  Th in 
tumor, (C) CD40+ Th1 in periphery (D) total CD40+ Th1 in tumor, (E) CD40+ Th1/17 
in periphery (F) total CD40+ Th1/17in tumor, (G) CD40+ Th17 in periphery (H) total 
CD40+  Th17 in tumor, (I) CD40+  Th22 in periphery and (J) total CD40+ Th22 in 
tumor in response to 4T1-WT mammary carcinoma over time. Tumor free (no tumor) 
mice were used as control.1.0x104 4T1-WT cells were injected and Th cell measured 
in individual mice days 7, 14, 21 and 28. Palpable tumors day 14. Statistical 
significance was measured using one-way ANOVA with Tukey’s multiple 
comparisons. Data are represented as means ± SEM and n= 4-11 mice. *p<0.05, 
**p<0.001, ***p<0.001 and ***p<0.0001.  
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Figure 19: CD40+ Th expansion in 4T1-WT vs. 4T1-IL6-KO tumor bearing Mice 
at day 28. Flow cytometric measurement of (A) total CD40+ Th, (B) CD40+ Th1 in 
periphery, (C) CD40+ Th1/17 in periphery, (D) CD40+ Th17 in periphery, and (E) 
total CD40+ Th22 in tumor in response to 4T1-WT mammary carcinoma over time. 
Statistical significance was measured using one-way ANOVA with Tukey’s multiple 
comparisons. Data are represented as means ± SEM and n= 4-11 mice. *p<0.05, 
**p<0.001, ***p<0.001 and ***p<0.0001.  
 
 
